ETON (Eton Pharmaceuticals) Shares Outstanding (EOP): 32.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ETON Eton Pharmaceuticals Inc ETON
57 GF Score
Price $58.51
GF Value $19.98
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Eton Pharmaceuticals Shares Outstanding (EOP)?

Eton Pharmaceuticals ETON +44.55% 57 Shares Outstanding (EOP) is 32.8 Mil as of Jun. 2026. GuruFocus rates ETON with a GF Score™ of 57/100 and a GF Value™ of $19.98 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Eton Pharmaceuticals's shares outstanding for the quarter that ended in Jun. 2026 was 32.8 Mil.

Eton Pharmaceuticals's quarterly shares outstanding increased from Mar. 2026 (27.4 Mil) to Jun. 2026 (32.8 Mil). It means Eton Pharmaceuticals issued new shares from Mar. 2026 to Jun. 2026 .

Eton Pharmaceuticals's annual shares outstanding increased from Dec. 2024 (26.7 Mil) to Dec. 2025 (27.0 Mil). It means Eton Pharmaceuticals issued new shares from Dec. 2024 to Dec. 2025 .


Eton Pharmaceuticals  (NAS:ETON) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Eton Pharmaceuticals Shares Outstanding (EOP) Related Terms


Eton Pharmaceuticals Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Eton Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eton Pharmaceuticals Shares Outstanding (EOP) Chart

Eton Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only 24.63 25.35 25.69 26.71 27.05

Eton Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.82 26.82 27.05 27.36 32.79

ETON vs COLL, ALVO, PCRX: Shares Outstanding (EOP) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eton Pharmaceuticals Shares Outstanding (EOP) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Eton Pharmaceuticals's Shares Outstanding (EOP) falls into.


ETON
57GF Score
Eton Pharmaceuticals Inc ETON
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eton Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 32.8 Mil mean?
Eton Pharmaceuticals (ETON) has a Shares Outstanding (EOP) of 32.8 Mil as of Jun. 2026. The total shares a company has outstanding, at period-end. View historical data on Eton Pharmaceuticals and its competitors.
Is Eton Pharmaceuticals' Shares Outstanding (EOP) too high?
Eton Pharmaceuticals' current Shares Outstanding (EOP) is 32.8 Mil. Overall, Eton Pharmaceuticals has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eton Pharmaceuticals' Shares Outstanding (EOP) compare to COLL and ALVO?
Eton Pharmaceuticals' Shares Outstanding (EOP) of 32.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Eton Pharmaceuticals and its competitors. Eton Pharmaceuticals's current Shares Outstanding (EOP) is 32.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eton Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Eton Pharmaceuticals (ETON) is currently considered Significantly Overvalued. The stock's GF Value™ is $19.98, compared to a current price of $58.51 — trading 192.8% above its estimated fair value. The current Shares Outstanding (EOP) is 32.8 Mil. Eton Pharmaceuticals' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Eton Pharmaceuticals (ETON), the current Shares Outstanding (EOP) is 32.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eton Pharmaceuticals (ETON) Overvalued in 2026?

Based on GuruFocus' analysis, Eton Pharmaceuticals stock appears to be overvalued. The current stock price of $58.51 is trading 192.8% above its estimated GF Value™ of $19.98. GuruFocus considers Eton Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ETON:

  • Shares Outstanding (EOP): 32.8 Mil
  • GF Value™: $19.98 vs. price of $58.51 (192.8% above fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the ETON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eton Pharmaceuticals Business Description

Address 21925 West Field Parkway, Suite 235, Deer Park, IL, USA, 60010-7278
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
57GF Score

Get the complete analysis for ETON

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$58.51
Price
$19.98
GF Value